Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Participation in B Riley Securities Radiopharma Conference

Tuesday, February 18, 2025 1 min read
Key Takeaway: Radiopharm Theranostics is participating in the B Riley Securities Radiopharma Conference. The company has recently received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, they have reported positive clinical updates across four programs, showcasing their ongoing commitment to advancing radiopharmaceuticals.
Price reaction · baseline $4.5 (2025-02-18T14:59:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics is actively participating in industry conferences.
  • The company has received IND approval from the US FDA.
  • Positive clinical updates have been reported across four programs.

Full Press Release Details

• Announcements
• February 18, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• November 26, 2021
• Announcements
• October 26, 2022
• Announcements
• January 24, 2024
• Announcements
• June 15, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What conference is Radiopharm Theranostics participating in?

Radiopharm Theranostics is participating in the B Riley Securities Radiopharma Conference.

What recent approval did Radiopharm receive?

The company received IND approval from the US FDA to initiate a Phase I study.

What product is being studied in the Phase I trial?

The Phase I trial is targeting B7H3 with the product BetaBart (RV-01).

How many clinical programs have positive updates?

Radiopharm has reported positive updates across four clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics B Riley Securities BetaBart Phase I study FDA approval
Last updated: Feb 18, 2025